We came across a bearish thesis on Intellia Therapeutics, Inc. on X.com by A_May_MD. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.'s share was trading at $8.10 as of December 2nd.
Intellia Therapeutics (NTLA) faces a severe credibility and valuation crisis following major safety concerns in both its lead gene-editing programs for hereditary angioedema (HAE) and transthyretin amyloidosis (ATTR). The company reported over $261 million in operating expenses in the first half of 2025, implying a current cash balance of roughly $500...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.